SELLAS Life Sciences Group
135 articles about SELLAS Life Sciences Group
-
SELLAS Announces Positive Phase 1 Data with CDK9 Inhibitor GFH009 Monotherapy in Patients with Relapsed/Refractory Hematologic Malignancies
12/13/2022
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), today announced positive results from its ongoing dose escalating Phase 1 first-in-human study of its highly selective CDK9 inhibitor, GFH009, in patients with relapsed and/or refractory (r/r) hematologic malignancies.
-
SELLAS Life Sciences’ CDK9 Inhibitor GFH009 Selected for Pediatric Preclinical in Vivo Testing (PIVOT) Program in Pediatric Cancers by the National Cancer Institute
12/6/2022
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that SELLAS’ highly selective CDK9 inhibitor, GFH009, will be evaluated in pediatric solid tumors and leukemia models through the National Cancer Institute (NCI) Pediatric Preclinical in Vivo Testing (PIVOT) Program.
-
SELLAS Life Sciences’ CDK9 Inhibitor GFH009 Demonstrates Tumor Growth Inhibition in Small Cell Lung Cancer Murine Model
12/1/2022
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”) today announced results from a preclinical in vivo study for its highly selective CDK9 inhibitor, GFH009, that demonstrate robust inhibition of tumor growth in a mouse xenograft model of small cell lung cancer (SCLC).
-
SELLAS Life Sciences to Participate in the JMP Securities Hematology and Oncology Summit
11/30/2022
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Company will present at the JMP Securities Hematology and Oncology Summit, a virtual investor conference being held from December 6-7, 2022.
-
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2022 Financial Results
11/14/2022
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and reported its financial results for the quarter ended September 30, 2022.
-
SELLAS Life Sciences Announces Update on Phase 3 REGAL Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia
11/14/2022
SELLAS Life Sciences Group, Inc. today announced important updates relating to its ongoing Phase 3 open-label registrational clinical trial (the REGAL study) for galinpepimut-S (GPS) in acute myeloid leukemia (AML) patients who have achieved complete remission following second-line salvage therapy (CR2 patients).
-
SELLAS Announces Confirmatory Top-Line Data Showing Survival and Clinical Benefits Based on the Final Analysis of the Phase 1/2 Clinical Trial of Galinpepimut-S
11/10/2022
SELLAS Life Sciences Group, Inc. today announced confirmatory top-line clinical data from the final analysis of results from its Phase 1/2 clinical trial of galinpepimut-S (GPS) in combination with Merck’s anti-PD-1 therapy, pembrolizumab (KEYTRUDA®), in patients diagnosed with WT1(+) relapsed or refractory platinum-resistant advanced metastatic ovarian cancer.
-
SELLAS Life Sciences to Present Data on its Highly Selective CDK9 Inhibitor, GFH009, at the 2022 American Society of Hematology (ASH) Annual Meeting
11/3/2022
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”) today announced that the Company will present data relating to its highly selective CDK9 inhibitor, GFH009, during two poster presentations at the American Society of Hematology (ASH) Annual Meeting being held on December 10-13, 2022 in New Orleans, Louisiana.
-
SELLAS Life Sciences Provides Webcast Information for Phase 3 REGAL Study Update on November 14, 2022
11/2/2022
SELLAS Life Sciences Group, Inc. today provides webcast information for its virtual investor event on November 14, 2022, at 8:30 a.m. ET. at which the Company will provide an update on its Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia.
-
SELLAS Life Sciences to Host Update Call on Phase 3 REGAL Study on November 14, 2022
10/17/2022
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it will host an update call on its Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML) on November 14, 2022.
-
SELLAS Life Sciences’ Licensee, 3D Medicines, Doses First Patient in Phase 1 Clinical Trial in China of Galinpepimut-S
10/11/2022
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”) today announced that 3D Medicines Inc., SELLAS’ licensee for the development and commercialization of its lead clinical candidate, galinpepimut-S (GPS), in China, Hong Kong, Macau and Taiwan, has dosed the first patient in its Phase 1 clinical trial in China of GPS (3D189 in China).
-
SELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 Formulations
9/29/2022
SELLAS Life Sciences Group, Inc. announced today data from a bioequivalence study for GFH009, its potent, highly selective, clinical-stage small molecule that inhibits cyclin-dependent kinase 9 (CDK9).
-
SELLAS Life Sciences Announces Poster Presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting
9/22/2022
SELLAS Life Sciences Group, Inc. today announced its upcoming poster presentation related to its highly selective CDK9 inhibitor, GFH009, at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) being held on September 28 through October 1, 2022.
-
SELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on September 15, 2022
9/8/2022
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reminds the investment community that it will host a virtual investor symposium on its lead asset, galinpepimut-S (GPS), including the potential commercial opportunity for GPS in AML patients.
-
SELLAS Life Sciences’ Highly Selective CDK9 Inhibitor, GFH009, Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Model of Neuroendocrine Prostate Cancer Cell Line
8/24/2022
SELLAS Life Sciences Group, Inc. today announced results from a new preclinical in vitro study for its highly selective CDK9 inhibitor, GFH009, in neuroendocrine prostate cancer (NEPC).
-
SELLAS Life Sciences’ Announces Election of Katherine Bach Kalin to its Board of DirectorsMs. Kalin Joins the Board with Decades of Life Sciences and Healthcare Industry Experience
8/16/2022
SELLAS Life Sciences Group, Inc. today announced the election of Katherine Bach Kalin to its Board of Directors.
-
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2022 Financial Results
8/11/2022
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, provided a business update and reported its financial results for the quarter ended June 30, 2022.
-
SELLAS Life Sciences’ GFH009 Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Studies in Solid Cancer and Acute Myeloid Leukemia Cell Lines
8/9/2022
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced results from preclinical in vitro studies for its highly selective CDK9 inhibitor, GFH009, in solid cancer and acute myeloid leukemia (AML) cell lines.
-
SELLAS Life Sciences Adds Once-a-Week Dose Cohort in Ongoing Phase 1 Clinical Trial with its Highly Selective CDK9 Inhibitor GFH009
7/7/2022
SELLAS Life Sciences Group, Inc. today announced that the Company has added a second, once-a-week dose cohort in its ongoing global Phase 1 clinical trial in both the United States and China with the highly selective CDK9 inhibitor GFH009 for patients suffering from advanced relapsed or refractory lymphoma and acute myeloid leukemia (AML).
-
SELLAS Life Sciences Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial
6/27/2022
SELLAS Life Sciences Group, Inc. today provided a clinical update on the ongoing Phase 1 dose-escalating clinical trial of GFH009, its novel and highly selective CDK9 inhibitor, in advanced relapsed and refractory lymphoma and acute myeloid leukemia (AML).